Shigella spp. Antimicrobial Drug Resistance, Papua New Guinea, 2000–2009 by Rosewell, Alexander et al.
LETTERS
were 33% and 46%, respectively, be-
fore 2002 and 73% and 79% in 2003–
2004 (7) and thus similar to those in 
our study.
In addition, resistances to cipro-
ﬂ  oxacin and ceftriaxone were <10%. 
Multidrug resistance (resistance to 
ampicillin, trimethoprim/sulfame-
thoxazole, and chloramphenicol) was 
observed in 63% of children in our 
study, compared with 7% in India, 
22% in Vietnam, and 65% in Pakistan 
(8–10).
More effort is needed in Africa 
to enable reliable and standardized 
laboratory diagnoses of Salmonella 
infections and to sustain TF surveil-
lance and drug sensitivity surveys. 
Moreover, introduction of a vaccina-
tion program should be discussed af-
ter more data are obtained from other 
areas in Ghana and West Africa. Such 
data currently are collected in an ex-
tensive standardized surveillance pro-
gram across the continent performed 
by our group and others. In parallel, 
trials should be conducted to assess 
the effectiveness and cost-effective-
ness of currently available and newly 
developed TF vaccines.
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Shigella spp. 
Antimicrobial Drug 
Resistance, Papua 
New Guinea, 2000–
2009
To the Editor: Approximately 
half the Shigella spp. infections in 
developing countries are caused by 
endemic shigellae (1), which in these 
countries are responsible for ≈10% of 
all episodes of diarrhea among chil-
dren <5 years of age and up to 75% of 
deaths from diarrhea (2). Deaths from 
epidemic Shigella spp. in the commu-
nity are estimated to outnumber deaths 
within the healthcare setting. In Papua 
New Guinea, diarrhea is a major cause 
of hospital admission and death (3); 
Shigella spp. are among the most com-
mon causes of enteric bacterial infec-
tion (4,5), and S. ﬂ  exneri is the most 
common serotype (3,6). Outbreaks of 
bloody diarrhea are frequently report-
ed; however, diagnosis in remote set-
tings is challenging, partly because the 
storage requirements for the organism 
are difﬁ  cult to meet.
Multidrug resistance of shigellae 
is not new (1); many countries have 
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reported resistance to amoxicillin, co-
trimoxazole, and chloramphenicol. For 
this reason, the World Health Organiza-
tion recommends that all patients with 
bloody diarrhea be treated with either 
ciproﬂ  oxacin or 1 of the 3 second-line 
drugs: pivmecillinam, azithromycin, 
and ceftriaxone (7). The antimicrobial 
drug currently recommended for pa-
tients with bloody diarrhea in primary 
healthcare settings in Papua New Guin-
ea is co-trimoxazole (8); ciproﬂ  oxacin 
is available only in hospitals.
In August 2009, an epidemic of 
multidrug-resistant  S.  ﬂ  exneri infec-
tion associated with widespread illness 
and death across 4 provinces of Papua 
New Guinea was reported to health 
authorities. To understand the trends 
and to inform antimicrobial drug poli-
cy makers, we reviewed retrospective 
microbiological data for 2000–2009. 
With the exception of 3 isolates col-
lected during an outbreak in the border 
regions of the 4 provinces during 2009 
(excluded from analysis), all isolates 
in our study were obtained as part of 
routine surveillance. Fecal samples 
were collected by clinicians from any 
patient seeking care for severe diarrhea 
at Port Moresby General Hospital. 
Before serologic testing was con-
ducted, samples were spread directly 
on desoxycholate citrate agar and 
MacConkey agar plates for culture. 
Antimicrobial drug resistance testing 
was performed by using the Kirby-
Bauer method.
From a total of 3,419 fecal samples 
cultured, 136 (4.0%) were positive for 
Shigella spp. The most commonly iso-
lated species was S. ﬂ  exneri (90.4%); 
less frequently isolated were S. boydii 
(3.7 %), S. dysenteriae (2.9%), and S. 
sonnei (1.5%). Of the 123 S. ﬂ  exneri 
isolates, 20 (16%) were further charac-
terized; the most frequent serovars were 
serovar 2 (40%) and serovar 3 (30%). 
Many (48%) Shigella spp.–positive 
isolates were from children <5 years of 
age. The highest rates of antimicrobial 
drug resistance of all Shigella spp. were 
to amoxicillin (96%), co-trimoxazole 
(86%), and chloramphenicol (60%); 
no resistance to ciproﬂ  oxacin and ce-
phalexin was found (Table).
Current evidence supports the 
use of ciproﬂ  oxacin, ceftriaxone, and 
pivmecillinam for treatment of bloody 
diarrhea (9). It also suggests that dys-
entery rarely relapses if an infected 
child has received a full course of 
treatment with 1 of these drugs and 
the causative pathogen is sensitive to 
the drug. Reducing the risk for relapse 
of bacterial infections among children 
is beneﬁ   cial because it reduces the 
likelihood of subsequent episodes of 
dysentery occurring in that child and 
of transmission to others (9). In our 
study, most isolates were resistant to 
co-trimoxazole and the other available 
antimicrobial drugs, indicating that 
their use would not have reduced ill-
ness and subsequent transmission in 
this setting. The lack of resistance to 
ciproﬂ  oxacin and cephalexin indicates 
that these drugs may be more effec-
tive; however, they are neither avail-
able at the primary healthcare level nor 
recommended in Papua New Guinea, 
which is cause for concern.
Surveillance for antimicrobial 
drug resistance is essential for the 
containment of antimicrobial drug 
resistance globally. However, interna-
tional surveillance depends on strong 
national surveillance systems. Despite 
the existence of a network of subna-
tional laboratories where fecal sample 
cultures had been performed, these 
laboratories no longer perform these 
cultures. In 1964, the laboratory in 1 
provincial hospital analyzed and sub-
typed 1,000 stool samples over a 15-
month period (6). In our study, con-
ducted at the national referral hospital 
(which limits the representativeness), 
we analyzed 3,419 fecal samples over 
a 10-year period.
Outbreaks of bloody diarrhea are 
common in remote settings in Papua 
New Guinea, yet with the exception of 
the 3 isolates from 2009 that were ex-
cluded from analysis, no Shigella spp.–
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Table. Antimicrobial drug resistance of Shigella spp., Papua New Guinea, 2000–2009* 
Drug 
Total no. 
isolates tested  Sensitivity
Shigella sp., no. (%) isolates 
S. boydi  S. dysenteriae S. flexneri  S. sonneii  Unknown sp. Total 
Amoxicillin  98 S 0 1 (33)  2 (2)  0 1 (100)  4 (4) 
R 3 (100)  2 (67)  87 (98)  2 (100)  0 94 (96) 
Cephalexin  46 S 2 (67)  2 (100)  38 (100)  2 (100)  1 (100)  45 (98) 
I 1 (33) 0 0 0 0 1 (2) 
R 0 0 0000
Ciprofloxacin  41 S 2 (67)  NA 35 (100)  1 (100)  2 (100)  40 (98) 
I 1 (33) NA 0 0 0 1 (2) 
R 0 0 0000
Chloramphenicol 114 S 0 2 (50)  9 (9)  2 (100)  1 (50)  14 (12) 
I 0 2 (50)  28 (28)  0 1 (50)  31 (27) 
R 4 (100)  0 64 (63)  0 0 68 (60) 
Naladixic acid  13 S 1 (100)  0 8 (100)  1 (100)  1 (50)  11 (85) 
R 0 1 (100)  0 0 1 (50)  2 (15) 
Co-trimoxazole  76 S 1 (25)  1 (33)  9 (14)  0 0 11 (14) 
R 3 (75)  2 (67)  57 (86)  2 (100)  1 (100)  65 (86) 
*S, sensitive; R, resistant, I, intermediate; NA, not applicable. LETTERS
positive samples have been identiﬁ  ed 
during outbreaks. Molecular methods 
may serve as an adjunct to traditional 
laboratory methods by improving sen-
sitivity and also enabling diagnosis of 
Shigella spp. outbreaks among remote 
populations where specimen storage 
and transport requirements may be 
challenging (10).
We describe extremely high rates 
of resistance of Shigella spp. to co-
trimoxazole, the recommended treat-
ment for bloody diarrhea in Papua 
New Guinea. Strengthening national 
surveillance for antimicrobial drug re-
sistance would provide the evidence to 
better inform policy decision makers. 
A review of the national antimicrobial 
drug policy for management of bloody 
diarrhea is urgently needed.
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Fatal Avian 
Inﬂ  uenza (H5N1) 
Infection in Human, 
China
To the Editor: Since the ﬁ  rst 
avian inﬂ   uenza virus (H5N1) was 
isolated from a goose in the southern 
region of the People’s Republic of 
China a decade ago (1), no poultry 
outbreak has been reported in Shan-
dong Province in eastern China, al-
though adjacent provinces have expe-
rienced an avian inﬂ  uenza epidemic 
(2). In fall 2008, several rounds of 
investigation of poultry farms and 
markets were conducted in Jinan, 
Shandong Province, and no inﬂ  uenza 
virus (H5N1) was isolated by reverse 
transcription–PCR (RT-PCR) from 
19,340 poultry oropharyngeal, cloa-
cal, and cage specimens.
However, a fatal inﬂ  uenza (H5N1) 
infection in a human was identiﬁ  ed on 
January 17, 2009 (3). The patient was 
a 27-year-old woman from Jinan. In-
ﬂ  uenza-like illness (ILI) developed on 
January 5, and the patient received in-
travenous ribavirin and cephalosporins 
on January 9. On January 11, she was 
hospitalized for fever (41°C) and re-
spiratory symptoms. On January 15, 
extensive inﬁ  ltration in both lungs de-
veloped; the diagnosis was pneumonia 
of unknown etiology. Early on January 
17, she underwent endotracheal intu-
bation. She died of acute respiratory 
distress syndrome and multiple organ 
failure later that day.
Two endotracheal aspirates col-
lected on January 17 were positive for 
inﬂ  uenza virus (H5N1) and for genes 
encoding matrix protein by real-time 
PCR and RT-PCR. However, throat 
swabs collected on January 15 and 
16 had been negative even after re-
peated testing (Table). The inﬂ  uenza 
virus (H5N1) was isolated on January 
22 after 48-hour culture and named 
A/Shandong/1/2009(H5N1). Whole-
genome sequencing showed that all 
segments were of avian origin. The 
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